Table 2.
Efficacy of canagliflozin at 26 weeks
| Hypoglycemic and weight effects of canagliflozin and canagliflozin plus metformin at 26 weeks in CANTATA-M and CANTATA-SU | ||
|---|---|---|
| Treatment | Change in Hgb A1C (%) | Change in weight (kg) |
|
| ||
| Placebo | +0.14 | −0.5 |
| Canagliflozin 100 mg | −0.77a | −2.5a |
| Canagliflozin 300 mg | −1.03a | −3.4a |
| Metformin plus glimepiride | −0.81 | +0.7 |
| Metformin plus canagliflozin 100 mg | −0.82b | −3.7c |
| Metformin plus canagliflozin 300 mg | −0.93b | −4c |
Notes:
a
P<0.001 compared to placebo;
b
canagliflozin was non-inferior when compared to glimepiride;
c
P<0.0001 compared to glimepiride.
Abbreviations: CANTATA-M, CANagliflozin Treatment and Trial Analysis-Monotherapy; CANTATA-SU, CANTATA-Sulfonylurea.